Gefitinib CAS 184475-35-2 Maʻemaʻe >99.5% (HPLC)
ʻO Shanghai Ruifu Chemical Co., Ltd. ka mea hana nui o Gefitinib (CAS: 184475-35-2) me ke kūlana kiʻekiʻe.Hiki iā Ruifu Chemical ke hāʻawi aku i ka honua holoʻokoʻa, ke kumukūʻai hoʻokūkū, ka lawelawe maikaʻi loa, ka liʻiliʻi a me ka nui nui i loaʻa.Kūʻai ʻo Gefitinib a me nā mea waena,Please contact: alvin@ruifuchem.com
| Inoa Kimia | ʻO Gefitinib |
| Nā huaʻōlelo like | Ke kahua kūʻokoʻa ʻo Gefitinib;Iressa;ZD1839;ZD-1839;N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4-Amine;N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-[3-(4-Morpholinyl)propoxy]-4-Quinazolinamine |
| Kūlana Kūʻai | Ma ke Kahua, Hana Hana Kūʻai |
| Helu CAS | 184475-35-2 |
| ʻĀpana Molekala | C22H24ClFN4O3 |
| Kaumaha Molecular | 446.91 g/mol |
| Lae hehee | 194.0 a i 198.0 ℃ |
| ʻO ka mānoanoa | 1.322±0.06 g/cm3 |
| Hiki i ka wai | ʻAʻole hiki ke hoʻonā i ka wai |
| Ka hikiwawe | Hiki ke hoʻoheheʻe ʻia ma DMSO |
| Waihona Temp. | Ka Mahana lumi |
| Hoʻouna | Ambient |
| COA & MSDS | Loaʻa |
| Ke kumu | Shanghai, Kina |
| Brand | Kemika Ruifu |
| Nā mea | Nā Kūlana Nānā | Nā hualoaʻa |
| Ka nana aku | Keʻokeʻo a hiki i ka pauda keʻokeʻo | Hoʻokō |
| Nalo ma ka maloo | <0.50% | 0.13% |
| Koena ma ka Ignition | <0.20% | 0.06% |
| Hoʻokahi haumia | <0.10% | 0.09% |
| Huina paumaele | <0.50% | 0.20% |
| Nā Metala Kaumaha (Pb) | ≤10ppm | <10ppm |
| Maʻemaʻe / Kaʻina Hanana | >99.5% (HPLC) | 99.80% |
| Infrared Spectrum | Kūlike me ka Hoʻolālā | Hoʻokō |
| 1H NMR Spectrum | Kūlike me ka Hoʻolālā | Hoʻokō |
| Ka hopena | Ua hoʻāʻo ʻia ka huahana a hoʻokō me nā kikoʻī i hāʻawi ʻia | |
Pūʻolo:ʻO ka ʻōmole Fluorinated, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E hoʻopaʻa paʻa i ka pahu a mālama i loko o kahi hale kūʻai maloʻo a me ka makani maikaʻi mai nā mea like ʻole.E pale i ka malamalama a me ka wai.
Hoʻouna:Hāʻawi i ka honua ma ka lewa, e FedEx / DHL Express.Hāʻawi wikiwiki a hilinaʻi hoʻi.
ʻAʻole no ka hoʻohana ʻana i nā kānaka.ʻAʻole no ka hoʻohana ʻana i nā diagnostics a i ʻole therapeutics.No ka noiʻi in vitro hoʻohana wale.
ʻAʻole e hāʻawi ʻia kekahi o nā huahana i nā ʻāina kahi e kūʻē ai kēia me nā patent e kū nei.Eia naʻe, aia ka kuleana hope i ka mea kūʻai aku.
Pehea e kūʻai ai?E ʻoluʻolu e kelepona maiDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 mau makahiki ʻike?Loaʻa iā mākou ma mua o 15 mau makahiki o ka ʻike i ka hana ʻana a me ka hoʻokuʻu ʻana aku i kahi ākea ākea o nā intermediates pharmaceutical kiʻekiʻe a i ʻole nā kemika maikaʻi.
Mākeke Nui?E kūʻai aku i ka mākeke kūloko, ʻAmelika ʻĀkau, ʻEulopa, India, Korea, Iapana, Australia, etc.
Nā pono?ʻO ke kūlana kiʻekiʻe, ke kumukūʻai kūpono, nā lawelawe ʻoihana a me ke kākoʻo ʻenehana, ka lawe wikiwiki ʻana.
ʻAno maikaʻiHōʻoiaʻiʻo?Pūnaehana hoʻomalu maikaʻi koʻikoʻi.ʻO nā lako ʻoihana no ka nānā ʻana ʻo NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Nā laʻana?Hāʻawi ka hapa nui o nā huahana i nā laʻana manuahi no ka loiloi maikaʻi, pono e uku ʻia ke kumukūʻai e nā mea kūʻai aku.
Hooia Hale Hana?Welina mai ka loiloi hale hana.E ʻoluʻolu e hoʻopaʻa manawa ma mua.
MOQ?ʻAʻohe MOQ.ʻAe ʻia ke kauoha liʻiliʻi.
Manawa Hoʻouna? Inā i loko o ka waihona, ʻekolu lā hoʻouna ʻia.
Kaʻahele?Ma ka Express (FedEx, DHL), ma ka Air, ma ke Kai.
Nā palapala?Ma hope o ka lawelawe kūʻai: COA, MOA, ROS, MSDS, etc.
Hoʻohui Kuʻuna?Hiki ke hāʻawi i nā lawelawe synthesis maʻamau e kūpono i kāu mau pono noiʻi.
Kūkākūkā uku?E hoʻouna mua ʻia ka invoice Proforma ma hope o ka hōʻoia ʻana o ke kauoha, hoʻopili ʻia kā mākou ʻike panakō.Uku e T/T (Telex Transfer), PayPal, Western Union, etc.
| Ka wehewehe palekana | 24/25 - Hōʻalo i ka pili ʻana me ka ʻili a me nā maka. |
| HS Code | 2934999099 |
ʻO Gefitinib (CAS: 184475-35-2) kahi lāʻau lapaʻau anti-tumor i hoʻolālā ʻia e AstraZeneca, UK.ʻO ia ka lāʻau lapaʻau mua i hoʻopaʻa ʻia no ka mālama ʻana i ka maʻi maʻi maʻi ʻaʻole liʻiliʻi.Hana ia ma ke kaohi ʻana i ke ala transduction hōʻailona o ka epidermal growth factor receptor tyrosine kinase (EGFR-TK).ʻO ka Epidermal Growth Factor (EGF) he polypeptide me ka nui molekala pili o 6.45 × 103, hiki ke hui pū me ka epidermal growth factor receptor (EGFR) ma ka membrane cell target e hana i nā hopena olaola.ʻO EGFR kahi mea hoʻokipa ʻano tyrosine kinase (TK).Ke hoʻopaʻa ʻia i ka EGF, hiki iā ia ke hoʻoikaika i ka hoʻoulu ʻana o TK i ke kino e loaʻa ana, ka hopena i ka autophosphorylation o nā koena tyrosine receptor, e hāʻawi ana i nā hōʻailona hoʻokaʻawale mau i nā cell, e hoʻonui ai i ka cell proliferation a me ka ʻokoʻa.Nui ka EGFR i loko o nā ʻiʻo kanaka a ua hōʻike nui ʻia i nā maʻi maʻi ʻino.Ma ka pale ʻana i ke ala hōʻailona EGFR ma ka ʻili o ke kelepona, keakea ʻo gefitinib i ka ulu ʻana o ka maʻi tumora, metastasis a me ka angiogenesis, a hiki ke hoʻoulu i ka apoptosis o nā cell tumor.I ʻAukake 2002, ua kūʻai mua ʻia ʻo gefitinib ma Iapana ma ke ʻano he lāʻau lapaʻau mua no ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi ma lalo o ka inoa kālepa ʻo Iressa.Ma Mei 2003, ua ʻae ka US Food and Drug Administration i ka gefitinib ma ke ʻano he kolu o ka monotherapy no nā poʻe maʻi me ka maʻi ʻaʻai maʻi ʻaʻole liʻiliʻi liʻiliʻi i hiki ʻole me nā lāʻau anticancer e pili ana i ka platinum a me ka docetaxel chemotherapy.I kēia manawa, ua ʻae ʻia e Australia, Iapana, Argentina, Singapore a me South Korea no ka mālama ʻana i ka maʻi maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi.Ma ka lā 28 o Pepeluali i ka makahiki 2005, ua ʻae ka China Food and Drug Administration i ka gefitinib no ka mālama ʻana i ka maʻi maʻi maʻi maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi kūloko (NSCLC) i loaʻa mua i ka chemotherapy.ʻAʻole ʻae ʻia i kēia manawa no ka hoʻohana ʻana i ka lāʻau lapaʻau mua no ka NSCLC kiʻekiʻe.Ma Iulai 1, 2009, ua ʻae ka European Medicines Agency i ka gefitinib no ka lālani mua, laina ʻelua a me ke kolu o ka lāʻau lapaʻau o ka maʻi maʻi maʻi ʻaʻai kūloko a i ʻole metastatic liʻiliʻi liʻiliʻi me ka EGFR gene mutations i nā pākeke.
